Taken all together, these data, obtained in large numbers of primary patient samples, corroborate our experimental findings on the tumor-suppressive role of EZH2 during AML induction and further implicate mutation of EZH2 as a poor prognostic factor in AML. The gene discussed is EZH2; the disease is acute myeloid leukemia.